跳至主要内容
临床试验/JPRN-UMIN000016539
JPRN-UMIN000016539已完成未知

THe effect of canagliflozin on active GLP-1 levels and betatrophin in patients with type 2 diabetes (CANARIA-STUDY) - THe effect of canagliflozin on active GLP-1 levels and betatrophin (CANARIA STUDY)

Dokkyo Medical University Koshigaya Hospital0 个研究点目标入组 40 人开始时间: 2015年2月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients with type 1 diabetes, pancreatic diabetes or secondary diabetes (Cushing syndrome, acromegaly etc.) diabetic coma or diabetic pre-coma, or type 1 diabetes 2)Patients who are not candidated for canagliflozin or teneligliptin treatment 3)Patients under insulin treatment 4)Heavy alcohol consumer (more than or equal to 60 g/day of pure alcohol ) 5)Patients under pregnancy, possible pregnancy, or lactation 6)Patients with severe renal dysfunction (Cr >2.4 mg/dL or Ccr <30 mL/min) 7)Furthermore, patients judged as inadequacy for participation in this study by medical doctor

研究者

发起方
Dokkyo Medical University Koshigaya Hospital

相似试验